AbbVie's Schizophrenia Drug Fails Trials, Boosting Bristol Myers Stock
TL;DR Summary
AbbVie's experimental schizophrenia drug, emraclidine, acquired through a $9 billion deal with Cerevel Therapeutics, failed to show significant patient improvement in Phase 2 trials. The drug did not outperform a placebo on the Positive and Negative Syndrome Scale (PANSS), leading AbbVie to reassess its next steps.
- Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials STAT
- AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. Barron's
- Crown jewel from AbbVie's Cerevel buyout fails two Phase 2 schizophrenia tests, Bristol Myers' stock soars Endpoints News
- Bristol Myers Rockets 12% On AbbVie's Schizophrenia Failure Investor's Business Daily
- JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news TipRanks
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
1 min
vs 1 min read
Condensed
73%
171 → 46 words
Want the full story? Read the original article
Read on STAT